SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (81687)6/19/2002 4:41:58 PM
From: Stockdoctor  Read Replies (2) | Respond to of 99280
 
Looks like biotechs and GENZ want to provide the "relentless" excuse for tommorow



To: Zeev Hed who wrote (81687)6/19/2002 4:47:21 PM
From: ajs  Read Replies (1) | Respond to of 99280
 
Zeev,

Any OB for GENZ?

16:04 ET GENZ Genzyme warns for FY02 (25.87 -1.04)
Company expects total revenues of between $1.10-$1.15 billion, approximately 4% lower than the previous guidance range -- the current Multex consensus estimate is for FY02 revs of $1.15 bln. Sees FY02 earnings in the range of $1.18-$1.23 per share, vs the current consensus estimate of $1.36 per share.



To: Zeev Hed who wrote (81687)6/19/2002 4:47:38 PM
From: r.edwards  Respond to of 99280
 
Zeev , check your mail . eom



To: Zeev Hed who wrote (81687)6/20/2002 1:26:03 AM
From: AD  Respond to of 99280
 
I have to agree on IRF. It'll come in further as semis splatter. It 's one of the best of the lot, but always gets sucked down with the other dogs.

IRF is high on my list of longs when this washes out. ....someday;-)
They're in a cutting edge space and have a good mgt team.
Buy low sell high. IRF 's a winner but ya have to let it wash.
AD


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News